EU Authorized Representative for Stent Manufacturers: Rule 8, Central Circulatory System and the Mandate
A stent is an implantable device, and Rule 8 of Annex VIII to Regulation (EU) 2017/745 sets its class by anatomy: class III in direct contact with the heart or the central circulatory system, class IIb elsewhere, and class III again when it elutes a medicinal substance or is absorbed. Implant card, summary of safety and clinical performance and 15-year retention apply to all of them. A stent manufacturer established outside the Union must designate a sole authorized representative under Article 11, and one mandate covers the EU and Türkiye.
Where the stent sits decides the class
A stent is an implantable device: it is totally introduced into the body by clinical intervention and remains after the procedure. Rule 8 is the starting point and its second indent turns on anatomy:
"All implantable devices and long-term surgically invasive devices are classified as class IIb unless they:" (MDR Annex VIII, Rule 8)
- "are intended to be used in direct contact with the heart, the central circulatory system or the central nervous system, in which case they are classified as class III;"
"‘Central circulatory system’ means the following blood vessels: arteriae pulmonales, aorta ascendens, arcus aortae, aorta descendens to the bifurcatio aortae, arteriae coronariae, arteria carotis communis, arteria carotis externa, arteria carotis interna, arteriae cerebrales, truncus brachiocephalicus, venae cordis, venae pulmonales, vena cava superior and vena cava inferior." (MDR Annex VIII, Section 2.6)
A coronary stent sits in the arteriae coronariae and a carotid stent in the arteria carotis, so both are class III; an iliac, femoral or renal stent sits outside that list and is class IIb. MDCG 2021-24 lists peripheral stents as class IIb, and vascular prosthesis and stents and spinal stents as class III.
Non-vascular stents: Rule 5 or Rule 8
A ureteral stent inserted through the urethra is invasive with respect to a body orifice, so Rule 5 applies rather than Rule 8:
"All invasive devices with respect to body orifices, other than surgically invasive devices, which are not intended for connection to an active device or which are intended for connection to a class I active device are classified as:" (MDR Annex VIII, Rule 5)
- "class IIb if they are intended for long-term use, except if they are used in the oral cavity as far as the pharynx, in an ear canal up to the ear drum or in the nasal cavity and are not liable to be absorbed by the mucous membrane, in which case they are classified as class IIa."
MDCG 2021-24 lists urethral stents as a class IIb example under that indent. A biliary, oesophageal or tracheal stent placed endoscopically for long-term use follows the same line and is class IIb; placed through a surgical incision it falls under Rule 8 and, outside the central circulatory and nervous systems, is still class IIb. Either way it is an implantable device under Article 2(5).
Drug-eluting and bioresorbable stents: Rules 14 and 8
"All devices incorporating, as an integral part, a substance which, if used separately, can be considered to be a medicinal product, as defined in point 2 of Article 1 of Directive 2001/83/EC, including a medicinal product derived from human blood or human plasma, as defined in point 10 of Article 1 of that Directive, and that has an action ancillary to that of the devices, are classified as class III." (MDR Annex VIII, Rule 14)
MDCG 2021-24 lists drug eluting stents as a class III example, and the notified body consults a medicines authority on the substance under Section 5.2 of Annex IX. A bioresorbable scaffold is wholly or mainly absorbed and is class III under the biological effect indent of Rule 8 wherever it is placed.
The delivery system is a separate device
The balloon catheter that delivers a coronary stent is classified in its own right under Section 3.2, and because it is used for minutes in the central circulatory system Rule 6 applies:
"All surgically invasive devices intended for transient use are classified as class IIa unless they:" (MDR Annex VIII, Rule 6)
- "are intended specifically to control, diagnose, monitor or correct a defect of the heart or of the central circulatory system through direct contact with those parts of the body, in which case they are classified as class III;"
MDCG 2021-24 lists stent delivery catheters and systems, with their guidewires and introducers, as class III under this indent. A delivery system for a peripheral stent used outside the central circulatory system is class IIa, and a stent sold pre-mounted on its delivery system takes the higher class under Section 3.5.
Implant card, SSCP and Article 54
"In addition, the manufacturer shall provide the information referred to in point (a) of the first subparagraph on an implant card delivered with the device." (MDR Article 18(1))
Stents are not on the exemption list of Article 18(3), so the implant card applies. Article 32 requires a summary of safety and clinical performance for every implantable device, validated by the notified body and published in EUDAMED. For class III implantable stents the notified body also follows the clinical evaluation consultation procedure that Article 54(1) prescribes for "class III implantable devices, and" (MDR Article 54(1)(a)).
Classification table for a stent portfolio
| Product variant | Class | Rule | Notified body |
|---|---|---|---|
| Coronary stent, bare metal | III | Rule 8, second indent | Yes; Article 54 consultation |
| Drug-eluting stent | III | Rule 14 (and Rule 8) | Yes; Article 54 and medicines authority consultation |
| Iliac, femoral, renal or other peripheral stent | IIb | Rule 8, general rule | Yes; per-device TD assessment, implant card, SSCP |
| Ureteral, biliary, oesophageal or tracheal stent placed through a body orifice, long term | IIb | Rule 5, third indent | Yes; implant obligations |
| Coronary stent delivery catheter, guidewire, introducer | III | Rule 6, first indent | Yes |
Conformity assessment: Article 52(3) and 52(4)
"Manufacturers of class III devices, other than custom-made or investigational devices, shall be subject to a conformity assessment as specified in Annex IX. Alternatively, the manufacturer may choose to apply a conformity assessment as specified in Annex X coupled with a conformity assessment as specified in Annex XI." (MDR Article 52(3))
A peripheral stent follows Article 52(4), and because it is a class IIb implantable device not listed in the second subparagraph of that Article, its technical documentation is assessed for every device rather than sampled. The clinical evaluation, the PMCF plan and the SSCP are part of the file the notified body reviews.
What the authorized representative mandate covers for stents
The appointment turns on where the manufacturer is established, not on the class of the device:
"Where the manufacturer of a device is not established in a Member State, the device may only be placed on the Union market if the manufacturer designates a sole authorised representative." (MDR Article 11(1))
Article 11(3) fixes the minimum tasks:
"The mandate shall require, and the manufacturer shall enable, the authorised representative to perform at least the following tasks in relation to the devices that it covers:" (MDR Article 11(3))
- "keep available a copy of the technical documentation, the EU declaration of conformity and, if applicable, a copy of the relevant certificate, including any amendments and supplements, issued in accordance with Article 56, at the disposal of competent authorities for the period referred to in Article 10(8);"
- "cooperate with the competent authorities on any preventive or corrective action taken to eliminate or, if that is not possible, mitigate the risks posed by devices;"
Stent field safety notices run through the competent authorities of every Member State where the device was implanted, so the mandate must cover corrective actions and incident reports.
One mandate for the European Union and Türkiye
Medex Kurumsal Danışmanlık acts as EU authorized representative under EUDAMED SRN TR-AR-000057550, with offices in Ankara and İstanbul. A manufacturer of stents established outside the EU and Türkiye does not need two representatives:
"manufacturers established outside the territory of the EU or Turkey only need to designate one authorised representative, either in the EU or in Turkey, in order to place medical devices on the market in the EU or in Turkey." (European Commission, Notice to Stakeholders, EU-Turkey Customs Union Agreement in the field of medical devices, March 2022, section I.2)
"The ’Union market’ refers to the territories of the European Union Member States, and due to the European Economic Area (EEA) is extended to Norway, Lichtenstein and Iceland, and via the Customs Union Agreement to Turkey." (MDCG 2022-16, footnote 1)
Our mandate covers the EU Member States and Türkiye; we are not a Swiss representative or UK Responsible Person, not a notified body, and we do not find importers or distributors. The published bands on our pricing page are €1,200 to 1,600 per year for class IIb, €1,500 to 2,000 per year for class III, with a €0 setup fee and rates fixed for three years from signature. Registration of the same stents in ÜTS (Ürün Takip Sistemi), Türkiye's product tracking system, is a separate service: ÜTS registration of stents in Türkiye (Turkish).
The symbol that identifies the representative on your label is explained in our guide to the EC REP meaning. If some devices are still placed on the market under the former directives, see the authorized representative for legacy devices.
Related device categories and country pages
Related groups: catheters, orthopedic implants and surgical sutures. All groups are listed on the medical device categories page, and the manufacturer country pages start from the EU authorized representative by country list.
Frequently asked questions
Why is a coronary stent class III and a femoral stent class IIb?
Rule 8 moves an implantable device to class III where it is intended for direct contact with the heart or the central circulatory system. Section 2.6 lists the arteriae coronariae; the femoral artery is not listed. MDCG 2021-24 gives peripheral stents as class IIb and vascular stents as class III.
Which class is a drug-eluting stent?
Class III under Rule 14, because it incorporates a substance that would be a medicinal product if used separately and that has an ancillary action. MDCG 2021-24 lists drug eluting stents, coronary and pulmonary, as an example.
Is the stent delivery catheter covered by the stent's certificate?
It is classified in its own right under Annex VIII, Section 3.2. A coronary delivery catheter is class III under the first indent of Rule 6, where MDCG 2021-24 lists stent delivery catheters and systems. A pre-mounted system takes the higher class under Section 3.5.
Does a ureteral stent need an implant card?
Yes. It is an implantable device under Article 2(5), class IIb under the long-term indent of Rule 5, and not on the exemption list in Article 18(3).
Does one mandate cover the European Union and Türkiye?
Yes. The European Commission's Notice of March 2022 confirms that a manufacturer established outside the EU and Türkiye only needs one authorized representative, established in the EU or in Türkiye. Medex is established in Türkiye under EUDAMED SRN TR-AR-000057550.
Sources and further reading
Regulation (EU) 2017/745 on medical devices (MDR), Articles 2, 10, 11, 18, 32, 52 and 54, Annex VIII - eur-lex.europa.eu
MDCG 2021-24, Guidance on classification of medical devices (October 2021) - health.ec.europa.eu
MDCG 2022-16, Guidance on authorised representatives (Regulation (EU) 2017/745 and Regulation (EU) 2017/746) - health.ec.europa.eu
European Commission, Notice to Stakeholders: EU-Turkey Customs Union Agreement in the field of medical devices (March 2022) - health.ec.europa.eu
Get a fixed-price EU REP quote for your stent and delivery system range (reply within 1 business day).
